A Study of ADR-001 in Patients With Liver Cirrhosis

Summary

This is a first-in-human Phase1/2 study of ADR-001, adipose-derived mesenchymal stem cells (AD-MSCs). The safety and preliminary efficacy are evaluated in Phase 1 in patients with liver cirrhosis caused by Hepatitis C or Nonalcoholic Steatohepatitis and a recommended Phase 2 dose is determined by the evaluation. The exploratory efficacy and safety are investigated against the same target population in Phase 2.

Timeline

Start

2017-07-20

Primary completion

2023-04-13

Completion

2023-04-13

Drugs

Indications